JP6479660B2 - Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン - Google Patents

Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン

Info

Publication number
JP6479660B2
JP6479660B2 JP2015528458A JP2015528458A JP6479660B2 JP 6479660 B2 JP6479660 B2 JP 6479660B2 JP 2015528458 A JP2015528458 A JP 2015528458A JP 2015528458 A JP2015528458 A JP 2015528458A JP 6479660 B2 JP6479660 B2 JP 6479660B2
Authority
JP
Japan
Prior art keywords
ror1
antibody
cells
cancer
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015528458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015532644A (ja
JP2015532644A5 (OSRAM
Inventor
トーマス ジェイムズ キップス
トーマス ジェイムズ キップス
チアン ユ
チアン ユ
ビン キュイ
ビン キュイ
リガン チェン
リガン チェン
ジョージ ウィドホップ
ジョージ ウィドホップ
チャールズ プルサク
チャールズ プルサク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2015532644A publication Critical patent/JP2015532644A/ja
Publication of JP2015532644A5 publication Critical patent/JP2015532644A5/ja
Application granted granted Critical
Publication of JP6479660B2 publication Critical patent/JP6479660B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015528458A 2012-08-24 2013-03-15 Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン Active JP6479660B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261693230P 2012-08-24 2012-08-24
US61/693,230 2012-08-24
US201261709055P 2012-10-02 2012-10-02
US61/709,055 2012-10-02
US201261709803P 2012-10-04 2012-10-04
US61/709,803 2012-10-04
PCT/US2013/032572 WO2014031174A1 (en) 2012-08-24 2013-03-15 Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019019281A Division JP6823094B2 (ja) 2012-08-24 2019-02-06 Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン

Publications (3)

Publication Number Publication Date
JP2015532644A JP2015532644A (ja) 2015-11-12
JP2015532644A5 JP2015532644A5 (OSRAM) 2016-06-02
JP6479660B2 true JP6479660B2 (ja) 2019-03-06

Family

ID=50150288

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015528458A Active JP6479660B2 (ja) 2012-08-24 2013-03-15 Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
JP2019019281A Active JP6823094B2 (ja) 2012-08-24 2019-02-06 Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
JP2021001318A Active JP7138735B2 (ja) 2012-08-24 2021-01-07 Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
JP2022141122A Pending JP2022174167A (ja) 2012-08-24 2022-09-06 Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019019281A Active JP6823094B2 (ja) 2012-08-24 2019-02-06 Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
JP2021001318A Active JP7138735B2 (ja) 2012-08-24 2021-01-07 Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
JP2022141122A Pending JP2022174167A (ja) 2012-08-24 2022-09-06 Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン

Country Status (20)

Country Link
US (5) US9758591B2 (OSRAM)
EP (3) EP3489261B1 (OSRAM)
JP (4) JP6479660B2 (OSRAM)
KR (3) KR101935088B1 (OSRAM)
CN (2) CN104662044B (OSRAM)
AU (3) AU2013306390B2 (OSRAM)
BR (1) BR112015003757B1 (OSRAM)
CA (1) CA2881966C (OSRAM)
CL (1) CL2015000431A1 (OSRAM)
DK (3) DK3489261T3 (OSRAM)
ES (3) ES2845184T3 (OSRAM)
IL (2) IL236962B (OSRAM)
MX (1) MX362456B (OSRAM)
MY (1) MY181648A (OSRAM)
NI (1) NI201500024A (OSRAM)
PH (1) PH12015500390B1 (OSRAM)
PL (2) PL2888283T3 (OSRAM)
PT (1) PT2888283T (OSRAM)
SG (1) SG11201500730XA (OSRAM)
WO (1) WO2014031174A1 (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101935088B1 (ko) * 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
WO2015131035A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
MX367787B (es) * 2014-07-29 2019-09-06 Cellectis Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
CA2956482A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
ES3034398T3 (en) 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
DK3189073T4 (da) 2014-09-04 2025-08-18 Cellectis Trofoblastglykoprotein (5t4, tpbg)-specifikke kimære antigenreceptorer til cancerimmunterapi
ES2850325T3 (es) 2014-10-09 2021-08-27 Engmab Sarl Anticuerpos biespecíficos contra CD3epsilon y ROR1
TWI718118B (zh) * 2015-01-16 2021-02-11 美商奇諾治療有限公司 針對ｒｏｒ１之特異性抗體及嵌合抗原受體
AU2016253149B2 (en) * 2015-04-24 2022-05-19 The Regents Of The University Of California Modulators of ROR1-ROR2 binding
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
EP3297671A4 (en) * 2015-05-18 2019-02-06 Eureka Therapeutics, Inc. ANTI-ROR1 ANTIBODY
EP3298046B1 (en) 2015-05-20 2025-02-12 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
WO2017038784A1 (ja) * 2015-08-28 2017-03-09 ロート製薬株式会社 Ｒｏｒ１陽性の間葉系幹細胞及びその調製方法、ｒｏｒ１陽性の間葉系幹細胞を含む医薬組成物及びその調製方法、並びにｒｏｒ１陽性の間葉系幹細胞を用いる疾患の予防又は治療方法
CA3001941A1 (en) * 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
RU2766190C2 (ru) 2016-01-20 2022-02-09 Дзе Скриппс Рисерч Инститьют Композиции антител к ror1 и соответствующие способы
TW201734049A (zh) * 2016-01-22 2017-10-01 健生生物科技公司 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法
ES2903228T3 (es) 2016-02-02 2022-03-31 Hutchinson Fred Cancer Res Anticuerpos anti-ROR1 y usos de los mismos
CN109311987A (zh) * 2016-05-13 2019-02-05 生物蛋白有限公司 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
WO2018119314A1 (en) * 2016-12-22 2018-06-28 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
CA3067829A1 (en) 2017-06-23 2018-12-27 VelosBio Inc. Ror1 antibody immunoconjugates
WO2019005636A2 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. ANTI-ROR1 ANTIBODIES AND METHODS OF PREPARATION AND USE
CN116041530A (zh) * 2017-06-25 2023-05-02 西雅图免疫公司 多特异性抗体及其制备和使用方法
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
EP3665193A1 (en) 2017-08-07 2020-06-17 NBE Therapeutics AG Anthracycline-based antibody drug conjugates having high in vivo tolerability
WO2019051135A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
WO2019079777A1 (en) 2017-10-20 2019-04-25 Fred Hutchinson Cancer Research Center COMPOSITIONS AND METHODS FOR TIGIT AND / OR CD112R TARGETING IMMUNOTHERAPY OR COMPRISING THE OVEREXPRESSION OF CD226
CN109836498A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向ror1的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
CN112041335A (zh) 2018-02-26 2020-12-04 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的组合物和方法
WO2019173843A1 (en) * 2018-03-09 2019-09-12 The Regents Of The University Of California Combination treatment of chemoresistant cancers
AU2019256431A1 (en) 2018-04-18 2020-11-05 Exelixis, Inc. Anti-ror antibody constructs
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
SG11202107976SA (en) 2019-01-29 2021-08-30 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
JP2022527081A (ja) * 2019-03-26 2022-05-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ）
WO2020237173A1 (en) * 2019-05-23 2020-11-26 VelosBio Inc. Anti-ror1/anti-cd3 bispecific binding molecules
EP4097137A4 (en) * 2020-01-30 2024-04-17 Oncternal Therapeutics, Inc. Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer
BR112022015416A2 (pt) 2020-02-07 2022-10-11 Velosbio Inc Anticorpos anti-ror1 e composições
CN112522206A (zh) * 2020-12-15 2021-03-19 苏州恒康生命科学有限公司 一种ror1基因敲除肿瘤细胞株的构建方法及其应用
GB202020154D0 (en) 2020-12-18 2021-02-03 Almac Discovery Ltd ROR1-specific variant antigen binding molecules
AU2022215847A1 (en) 2021-02-02 2023-08-10 Numab Therapeutics AG Multispecific antibodies having specificity for ror1 and cd3
WO2022182891A1 (en) 2021-02-25 2022-09-01 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CN117440973A (zh) * 2021-04-09 2024-01-23 索伦托药业有限公司 与ror1结合的抗原结合蛋白
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CN118043080A (zh) 2021-08-13 2024-05-14 昆山新蕴达生物科技有限公司 一种基于微管抑制剂的抗体偶联药物
US20240392033A1 (en) 2021-08-24 2024-11-28 Kunshan Xinyunda Biotech Co., Ltd. Antibody-drug conjugate conjugated via breakable linker
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
JP2024545138A (ja) 2021-12-09 2024-12-05 クンシャン シンユンター バイオテック カンパニー，リミティド 親和性が改善された抗体薬物複合体、その調製法、及びその応用
CN116836286A (zh) 2022-09-07 2023-10-03 中国科学院合肥物质科学研究院 能够特异性结合ror1的抗体、其偶联药物及其制备方法和应用
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5219837A (en) 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE175118T1 (de) 1990-10-05 1999-01-15 Medarex Inc Gezielte immunostimulierung mit bispezifischen stoffen
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
JP3431140B2 (ja) 1991-04-26 2003-07-28 サーフィス・アクティブ・リミテッド 抗体およびその使用方法
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5843749A (en) 1991-07-26 1998-12-01 Regeneron Pharmaceuticals, Inc. Ehk and Ror tyrosine kinases
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
EP0807173B1 (en) 1994-12-30 2007-08-08 Planet Biotechnology, Inc. Methods for producing immunoglobulins containing protection proteins in plants and their use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69632465T2 (de) 1995-06-07 2005-06-23 Ortho-Mcneil Pharmaceutical, Inc. Cdr-transplantierte antikörper gegen "tissue factor" und verfahren zur deren verwendung
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6001575A (en) 1997-03-19 1999-12-14 Johns Hopkins University Therapeutic uses of grip and grip-related molecules
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
WO1999025818A1 (en) 1997-11-17 1999-05-27 Peter Kufer Method of identifying binding site domains that retain the capacity of binding to an epitope
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6605709B1 (en) 1999-04-09 2003-08-12 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics
AU4574501A (en) 2000-03-17 2001-10-03 Millennium Pharm Inc Method of inhibiting stenosis and restenosis
DK1294769T3 (da) 2000-06-16 2011-04-26 Human Genome Sciences Inc Antistoffer der immunspecifikt binder til BLyS
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
US20140072979A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
AU2002245272B2 (en) 2001-01-16 2006-06-29 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20140072980A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
JP2004538324A (ja) 2001-08-03 2004-12-24 メディカル リサーチ カウンシル 細胞内抗体
CN101799476B (zh) 2001-08-23 2013-01-02 Rsr有限公司 筛选针对tsh受体的自身抗体的试剂盒
US7226594B2 (en) 2001-11-07 2007-06-05 Agensys, Inc. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
ATE444308T1 (de) 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2004009805A1 (ja) 2002-07-19 2004-01-29 Japan Science And Technology Agency 新規抗体酵素生産方法、新規抗体酵素、およびその利用
SI2301965T1 (sl) 2002-10-16 2015-07-31 Purdue Pharma L.P. Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
EP1608684A2 (en) 2003-02-07 2005-12-28 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
JP5010281B2 (ja) 2003-05-31 2012-08-29 マイクロメット アクツィエン ゲゼルシャフト Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物
US7569389B2 (en) 2004-09-30 2009-08-04 Ceres, Inc. Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
DK1691837T3 (da) 2003-12-10 2012-10-01 Medarex Inc IP-10-antistoffer og anvendelse heraf
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
DK1709081T3 (da) 2004-01-16 2011-06-06 Regeneron Pharma Fusionspolypeptider, der kan aktivere receptorer
DK1716178T3 (da) 2004-02-16 2010-09-20 Micromet Ag Mindre immunogene bindingsmolekyler
CA2555820C (en) 2004-02-19 2016-01-19 Genentech, Inc. Cdr-repaired antibodies
US7192709B2 (en) 2004-03-15 2007-03-20 Digigenomics Co., Ltd. Methods for identification, assessment, prevention, and therapy of cancer
US7504086B2 (en) 2004-03-31 2009-03-17 Canon Kabushiki Kaisha Structure and method for releasing substance therefrom
MXPA06011538A (es) * 2004-04-06 2007-01-26 Univ California Tirosina cinasa de receptor huerfano como un objetivo en cancer de mama.
KR100914377B1 (ko) 2004-04-22 2009-08-28 프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우 스트랩토코쿠스 표면 항원 Ⅰ/Ⅱ와 특이적으로 결합하는ｄｉａｂｏｄｙ 및 이의 이용 방법
CA2564432A1 (en) 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid .beta. peptide antibody and fragment of said antibody
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
JP2008507592A (ja) 2004-06-09 2008-03-13 ジェネンテック・インコーポレーテッド 環状肉芽腫又はサルコイドの治療法
CA2576277A1 (en) 2004-08-16 2006-02-23 Cropdesign N.V. Plants having improved growth characteristics and method for making the same
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP1805222B1 (en) 2004-10-01 2011-02-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antibodies directed to the mammalian eag1 ion channel protein
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7700098B2 (en) 2005-01-27 2010-04-20 Novimmune Sa Anti-interferon gamma antibodies and methods of use thereof
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
KR101188117B1 (ko) 2005-03-31 2012-10-09 바이오메딕스 인코포레이티드 항ｃｄ20 모노클로날 항체
JP5004154B2 (ja) 2005-04-06 2012-08-22 一般財団法人化学及血清療法研究所 組換え抗ボツリヌス神経毒素抗体
EA016038B1 (ru) 2005-04-22 2012-01-30 Эли Лилли Энд Компани Антитело к tgf-бета и его применение
WO2006138005A2 (en) 2005-05-10 2006-12-28 Monsanto Technology, Llc Genes and uses for plant improvement
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
SG165322A1 (en) 2005-08-31 2010-10-28 Schering Corp Engineered anti-il-23 antibodies
EP1948680A4 (en) 2005-10-28 2010-01-13 Univ California METHOD AND COMPOUNDS FOR DETECTING AND ISOLATING LYMPHOMA CELLS
WO2008103849A2 (en) * 2007-02-21 2008-08-28 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
CA2627075A1 (en) 2005-11-14 2007-05-18 Bioren, Inc. Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening
EP2548954A1 (en) 2006-02-14 2013-01-23 Verenium Corporation Xylanases, nucleic acids encoding them and methods for making and using them
JPWO2007102200A1 (ja) 2006-03-07 2009-07-23 国立大学法人大阪大学 抗ｃｄ２０モノクローナル抗体
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
EP2423231A3 (en) 2006-08-18 2012-05-30 Novartis AG PRLR-specific antibody and uses thereof
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
FR2909092B1 (fr) 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
JP2010512791A (ja) 2006-12-22 2010-04-30 シェーリング コーポレイション Ｃｄ２００ｒに対する抗体
WO2008097439A2 (en) 2007-02-07 2008-08-14 The Trustees Of The University Of Pennsylvania Anti-autoimmune antibodies for treatment of pemphigus
US9745367B2 (en) 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
US20100129817A1 (en) 2007-05-03 2010-05-27 Regeneron Pharmaceuticals Inc. Identifying germline competent embryonic stem cells
CN101743253B (zh) 2007-05-17 2013-05-08 健泰科生物技术公司 神经毡蛋白片段与神经毡蛋白抗体复合物的晶体结构
US8546546B2 (en) 2007-07-04 2013-10-01 Forerunner Pharma Research Co., Ltd. Anti-Muc 17 antibody
US8299318B2 (en) 2007-07-05 2012-10-30 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
US8119130B2 (en) 2007-07-25 2012-02-21 Medimmune Limited Targeted binding agents directed to KDR and uses thereof—035
WO2009031230A1 (ja) 2007-09-06 2009-03-12 Osaka University 抗ｃｄ２０モノクローナル抗体
US8362325B2 (en) 2007-10-03 2013-01-29 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
WO2009064944A2 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
WO2009072604A1 (ja) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 抗nr10抗体、およびその利用
ES2425269T3 (es) 2007-12-14 2013-10-14 Bristol-Myers Squibb Company Moléculas de unión al receptor OX40 humano
EP2231186A4 (en) 2007-12-17 2012-08-08 Dyax Corp COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US8637026B2 (en) 2007-12-26 2014-01-28 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
WO2009097128A1 (en) 2008-01-29 2009-08-06 Ludwig Institute For Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
US9029636B2 (en) 2008-02-05 2015-05-12 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
MX2010008786A (es) 2008-02-11 2010-12-01 Curetech Ltd Anticuerpos monoclonales para tratamiento de tumores.
US8008445B2 (en) 2008-03-03 2011-08-30 Dyax Corp. Metalloproteinase 9 binding proteins
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
EP2282757B1 (en) 2008-04-07 2013-05-22 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
WO2009129538A2 (en) 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
US8410251B2 (en) 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
EP2313109A2 (en) 2008-07-02 2011-04-27 Emergent Product Development Seattle, LLC Il6 immunotherapeutics
CA3022196A1 (en) 2008-07-16 2010-01-21 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US8710022B2 (en) 2008-07-18 2014-04-29 National University Corporation Nagoya University Cell proliferation inhibitor
EP2669379A3 (en) 2008-07-31 2014-03-19 BASF Plant Science GmbH Plants having modified growth characteristics and a method for making the same
NZ591098A (en) 2008-08-20 2012-08-31 Centocor Ortho Biotech Inc Engineered anti-il-13 antibodies, compositions, methods and uses
JP5781932B2 (ja) 2008-11-03 2015-09-24 アレシア・バイオセラピューティクス・インコーポレーテッド 腫瘍抗原の生物活性を特異的にブロックする抗体
US8183346B2 (en) 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
US9012723B2 (en) 2009-01-16 2015-04-21 Monsanto Technology Llc Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits
US8673307B1 (en) 2009-03-09 2014-03-18 The Rockefeller University HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
KR101346530B1 (ko) 2009-03-20 2013-12-31 암젠 인크 알파-4-베타-7 이종이량체 특이적 길항제 항체
RU2542394C2 (ru) 2009-03-24 2015-02-20 ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. Гуманизированные антитела против light и их применение
RU2568066C2 (ru) 2009-03-25 2015-11-10 Дженентек, Инк. Антитела против fgfr3 и способы их применения
WO2010117455A2 (en) 2009-04-08 2010-10-14 U.S. Army Medical Research Institute Of Infectious Diseases Human monoclonal antibodies protective against bubonic plaque
US9090679B2 (en) 2009-04-17 2015-07-28 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
EP2421899B1 (en) * 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-human ror1 antibodies
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102656189B (zh) 2009-08-13 2014-10-08 克鲁塞尔荷兰公司 针对人呼吸道合胞病毒(rsv)的抗体以及使用方法
PL2470671T3 (pl) 2009-08-28 2015-05-29 Regeneron Pharma Przeciwciała antykinowe wiążące się z wieloma chemokinami CC
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
US8592559B2 (en) 2009-10-30 2013-11-26 Toray Industries, Inc. Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof
EP2496605A1 (en) 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
NZ716587A (en) 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
US8937159B2 (en) 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
WO2011100566A2 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
TW201141519A (en) 2010-03-04 2011-12-01 Symphogen As Anti-HER2 antibodies and compositions
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2011123859A1 (en) 2010-04-02 2011-10-06 Skyfire Labs, Inc. Assisted hybrid mobile browser
EP2556085A2 (en) 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
CA2799746C (en) 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
JP2012021943A (ja) 2010-07-16 2012-02-02 National Cancer Center 子宮体がんの検査方法、子宮体がんの検査薬、並びに子宮体がん抗原に対する抗体
US9163258B2 (en) 2010-07-23 2015-10-20 Fred Hutchinson Cancer Research Center Method for the treatment of obesity
EP2619228A1 (en) 2010-09-22 2013-07-31 Novo Nordisk A/S Therapeutic factor viii antibodies
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
AU2011320314B2 (en) 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
CA2818992C (en) * 2010-12-01 2021-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2012097313A2 (en) * 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
JP2014506580A (ja) 2011-02-14 2014-03-17 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
NZ724296A (en) 2011-05-13 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
AU2012295394B2 (en) 2011-08-12 2016-04-14 Omeros Corporation Anti-FZD10 monoclonal antibodies and methods for their use
PT2758073T (pt) 2011-09-23 2019-02-01 Oncomed Pharm Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
EP2617319A1 (en) 2012-01-17 2013-07-24 Braun GmbH Head portion and handle portion of an oral care device
PL2818483T3 (pl) 2012-02-21 2018-01-31 Toray Industries Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
KR102009238B1 (ko) 2012-02-21 2019-08-09 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
NZ628804A (en) 2012-02-24 2017-08-25 Abbvie Stemcentrx Llc Dll3 modulators and methods of use
JP6280031B2 (ja) 2012-03-29 2018-02-14 中外製薬株式会社 抗ｌａｍｐ５抗体およびその利用
DK2832366T3 (en) 2012-03-30 2018-01-22 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF Gallbladder cancer
CN104220095B (zh) 2012-03-30 2016-09-07 东丽株式会社 肝癌的治疗和/或预防用药物组合物
JP6244350B2 (ja) 2012-04-03 2017-12-06 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
SG11201407106XA (en) 2012-05-01 2014-11-27 Genentech Inc Anti-pmel17 antibodies and immunoconjugates
WO2013172961A1 (en) 2012-05-14 2013-11-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN103421113B (zh) 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 抗BLyS抗体
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
CN103792364B (zh) 2012-10-31 2016-06-08 张宝弘 用于检测外周血中循环肿瘤细胞ror1蛋白的试剂及其应用
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
ME03394B (me) 2013-02-22 2020-01-20 Medimmune Ltd Antidllз-antitelo-pbd konjugati i nihovа upotreba
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
WO2014174111A1 (en) 2013-04-26 2014-10-30 Pierre Fabre Medicament Axl antibody-drug conjugate and its use for the treatment of cancer
HRP20240107T1 (hr) 2013-05-20 2024-04-12 F. Hoffmann - La Roche Ag Protutijela na transferinski receptor i postupci uporabe
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
BR112016004073A8 (pt) 2013-08-28 2018-06-12 Stemcentrx Inc Anticorpos criados por engenharia, conjugados de anticorpo fármaco, seu método de preparação e seu uso, composição farmacêutica e seu uso, kits, e métodos para administrar uma pirrolobenzodiazepina (pbd) a uma célula de câncer que expressa dll3 e para determinar a citotoxicidade de um conjugado de anticorpo fármaco anti-dll3
US10053511B2 (en) 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
RU2725520C2 (ru) 2013-12-11 2020-07-02 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
TW201533060A (zh) 2013-12-13 2015-09-01 Genentech Inc 抗ｃｄ３３抗體及免疫結合物
EP3736292B1 (en) 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP3086809A4 (en) 2013-12-24 2017-11-29 NovelMed Therapeutics, Inc. Compositions and methods of treating ocular diseases
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
DK3126381T4 (da) 2014-04-01 2022-04-04 Biontech Cell&Gene Therapies Gmbh Claudin-6-specifikke immunoreceptorer og t-celleepitoper
WO2015162293A1 (en) 2014-04-25 2015-10-29 Pierre Fabre Medicament Antibody-drug-conjugate and its use for the treatment of cancer

Also Published As

Publication number Publication date
KR20190000925A (ko) 2019-01-03
ES2992753T3 (en) 2024-12-17
KR20150046111A (ko) 2015-04-29
US20150232569A1 (en) 2015-08-20
PH12015500390A1 (en) 2015-04-27
EP2888283A4 (en) 2016-07-13
CN104662044B (zh) 2018-10-30
AU2018241099A1 (en) 2018-10-25
JP2015532644A (ja) 2015-11-12
DK2888283T3 (en) 2018-11-19
PL3489261T3 (pl) 2021-08-16
JP2022174167A (ja) 2022-11-22
EP2888283B1 (en) 2018-09-19
JP6823094B2 (ja) 2021-01-27
US20190389962A1 (en) 2019-12-26
EP3489261B1 (en) 2020-10-21
IL264057A (en) 2019-01-31
CA2881966C (en) 2020-10-06
JP2019110906A (ja) 2019-07-11
BR112015003757B1 (pt) 2022-08-16
KR20200079561A (ko) 2020-07-03
SG11201500730XA (en) 2015-02-27
US20230110249A1 (en) 2023-04-13
BR112015003757A2 (pt) 2017-11-28
EP3489261A1 (en) 2019-05-29
ES2702315T3 (es) 2019-02-28
AU2013306390B2 (en) 2018-07-05
AU2020267172A1 (en) 2020-12-03
JP7138735B2 (ja) 2022-09-16
CN109369808A (zh) 2019-02-22
DK3838923T3 (da) 2024-07-29
CL2015000431A1 (es) 2016-02-26
CN104662044A (zh) 2015-05-27
CA2881966A1 (en) 2014-02-27
ES2845184T3 (es) 2021-07-26
MX362456B (es) 2019-01-18
AU2018241099B2 (en) 2020-08-13
WO2014031174A1 (en) 2014-02-27
CN109369808B (zh) 2023-11-07
JP2021058215A (ja) 2021-04-15
US12162950B2 (en) 2024-12-10
DK3489261T3 (da) 2020-12-14
AU2013306390A1 (en) 2015-02-26
PL2888283T3 (pl) 2019-03-29
EP2888283A1 (en) 2015-07-01
MX2015002337A (es) 2015-08-14
EP3838923B1 (en) 2024-05-01
KR102134088B1 (ko) 2020-07-14
EP3838923A1 (en) 2021-06-23
US20180066063A1 (en) 2018-03-08
NI201500024A (es) 2015-07-16
US11312787B2 (en) 2022-04-26
US10344096B2 (en) 2019-07-09
US20250282888A1 (en) 2025-09-11
PH12015500390B1 (en) 2021-12-10
IL264057B (en) 2020-03-31
IL236962B (en) 2019-01-31
KR101935088B1 (ko) 2019-01-04
US9758591B2 (en) 2017-09-12
KR102312856B1 (ko) 2021-10-13
PT2888283T (pt) 2018-11-16
MY181648A (en) 2020-12-30

Similar Documents

Publication Publication Date Title
JP7138735B2 (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
HK40055783B (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
HK40055783A (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗
HK40005045A (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190206

R150 Certificate of patent or registration of utility model

Ref document number: 6479660

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250